The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Impact of solid state properties on developability assessment of drug candidates
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Encyclopedia of Pharmaceutical Technology
Swarbrick, J. (2013) · CRC Press eBooks · doi:10.1201/b19309 · Cited by 1,794
Remington: The science and practice of pharmacy
(1996) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(96)90065-6 · Cited by 1,433
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Hancock, B. C., & Parks, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007516718048 · Cited by 1,358
Polymorphism in Pharmaceutical Solids
(2018) · CRC Press eBooks · doi:10.3109/9781420073225 · Cited by 1,099
Solid state chemistry of drugs
Byrn, S. R. (1982) · Medical Entomology and Zoology · Cited by 1,086
Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development
Chemburkar, S. R., Bauer, J., Deming, K., Spiwek, H., Patel, K., Morris, J., Henry, R., Spanton, S., Dziki, W., Porter, W., et al. (2000) · Organic Process Research & Development · doi:10.1021/op000023y · Cited by 687
Solubility and Solubilization in Aqueous Media
Yalkowsky, S. H. (1999) · Cited by 669
Bevan, C. D., & Lloyd, R. S. (2000) · Analytical Chemistry · doi:10.1021/ac9912247 · Cited by 345
High throughput physicochemical profiling for drug discovery
Kerns, E. H. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1134 · Cited by 343
Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate
Aguiar, A. J., Krc, J., Kinkel, A. W., & Samyn, J. C. (1967) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600560712 · Cited by 307
Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities
Bastin, R. J., Bowker, M. J., & Slater, B. J. (2000) · Organic Process Research & Development · doi:10.1021/op000018u · Cited by 245
Testa, B., Krämer, S. D., Wunderli‐Allenspach, H., & Folkers, G. (2006) · Cited by 166
Water-Insoluble Drug Formulation
Ron, L. (2000) · CRC Press eBooks · doi:10.1201/9781420026054 · Cited by 119
Chemical Kinetics and Drug Stability
Attwood, D., & Poust, R. I. (2009) · CRC Press eBooks · doi:10.3109/9781420065657-10 · Cited by 26
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
Pharmaceutical cocrystals: An overview
Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., & Trappitt, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.037 · Cited by 665
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs
Censi, R., & Di Martino, P. (2015) · Molecules · doi:10.3390/molecules201018759 · Cited by 512
Bridging solubility between drug discovery and development
Di, L., Fish, P. V., & Mano, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.007 · Cited by 491
Metadata
- Authors
- Huang, L.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2004-02-23
- Volume
- 56
- Issue
- 3
- Pages
- 321-334
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2057302806
- Cited by
- 438
- References
- 16
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.